CERN Accelerating science

Početna stranica > CERN Experiments > MEDICIS Internal Notes

MEDICIS Internal Notes

Pretražite 32 zapise za:
Savjeti za pretraživanje :: Jednostavno pretraživanje
Added/modified since: do:
Sortiraj po: Prikaz rezultata: Oblik izlaznih podataka:
Najnovije dodano:
2021-11-07
23:57
PRISMAP – The European medical radionuclide programme: CERN-MEDICIS contribution / Stora, Thierry (CERN)
PRISMAP is the European medical radionuclide programme on the production of high purity radionuclides (radioactive isotopes) by mass separation (www.prismap.eu). We federate a European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment. [...]
MED-032.- Geneva : CERN, 2021 - 2. Fulltext: DOC;

Detaljnije - Slični zapisi
2021-03-01
19:20
Theranostics studies using 152/149Tb-labeled anti-CXCR4 probes in tumor mice / Cleeren, Frederik (KU Leuven)
The chemokine receptor CXCR4 is a seven transmembrane G protein-coupled receptor and is involved in various inflammatory and autoimmune diseases, as well as in cancer metastasis and progression. Binding of the endogenous ligand CXCL12 (also known as stromal cell-derived factor-1α (SDF-1α)) to CXCR4 leads to activation of downstream signaling pathways that exert critical functions in development (organogenesis), normal physiology as well in disease processes. [...]
MED-031.- Geneva : CERN, 2021 - 4. Fulltext: PDF;

Detaljnije - Slični zapisi
2021-03-01
19:08
Targeted Alpha Therapy research in Belgium: qualifying the 225Ac pipeline / Cocolios, Thomas Elias (KU Leuven (BE)) ; Cleeren, Frederick (KU Leuven)
Targeted Alpha Therapy (TAT) is a very promising form of targeted radionuclide therapy thanks to the high linear energy transfer of the heavy alpha particles. The isotope 225Ac is particularly attractive as its relatively long half-life (T1/2=10 days) is appropriate for vector molecules with longer biological half-life (e.g. [...]
MED-030.- Geneva : CERN, 2021 - 4. Fulltext: 3.PDF;

Detaljnije - Slični zapisi
2021-02-26
09:23
CHUV Proposal II): "Preclinical study of the PSMA-I&T tracer radiolabeled with the in vivo generator 134Ce/134La in a prostate cancer model" / Viertl, David (CHUV)
Project proposal II) from CHUV to the MEDICIS Collaboration board of March 2021 Request for production of 134Ce/134La to be used as an in vivo generator to be tested in the context of preclinical prostate cancer model for imaging and treatment..
MED-029.- Geneva : CERN, 2021 - 3. Preclinical study of the PSMA-I&T tracer radiolabeled with the in vivo generator 134Ce/134La in a prostate cancer model: DOC;

Detaljnije - Slični zapisi
2021-02-26
09:17
CHUV proposal I: "Study of the 128Ba/128Cs in vivo generator in a preclinical model of osteosarcoma" / Viertl, David (CHUV)
Project proposal I) from CHUV to MEDICIS Collaboration board of March 2021 Request for production of 128Ba/128Cs to be used as an in vivo generator to be tested preclinically in the context of osteosarcoma imaging and treatment..
MED-028.- Geneva : CERN, 2021 - 2. Study of the 128Ba/128Cs in vivo generator in a preclinical model of osteosarcoma: DOC;

Detaljnije - Slični zapisi
2020-09-14
19:12
Strengthening theranostics or radionuclide therapy in Pakistan / Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
In this project, we are interested to strengthen theranostics or radionuclide therapy in Pakistan. Due to its ability of targeting only cancerous cells, the field of theranostics is rapidly emerging worldwide and in developed countries, it is considered as real cancer diagnosis and treatment modality. [...]
MED-027.- Geneva : CERN, 2020 - 6. Fulltext: DOCX;

Detaljnije - Slični zapisi
2020-09-14
15:50
Facilities and Expertise in nuclear medicine / Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
This technical note is submitted following the accession of Pakistan to the MEDICIS collaboration as endorsed at the 5th Board, and required as follow-up..
MED-026.- Geneva : CERN, 2020 - 2. clinical qualification for radioisotopes: DOC;

Detaljnije - Slični zapisi
2020-02-17
09:50
Mass separation for the production of high specific activity Samarium-153 for targeted radionuclide therapy / Cocolios, Thomas Elias (KU Leuven (BE))
The radiolanthanide samarium-153 possesses highly favorable decay characteristics for nuclear medicine applications. 153Sm has a half-life of 1.93 d, decays into a stable daughter nuclide (153Eu) and emits β- particles (Emax = 705 keV, 635 keV) and γ photons (103 keV) suitable for therapy and SPECT imaging, respectively. [...]
MED-025.- Geneva : CERN, 2020 - 3. Sm-153 separation: PDF;

Detaljnije - Slični zapisi
2019-09-16
08:10
Mass separation of 225Ac from 227Ac and from irradiated Th targets to support Targeted Alpha Therapy / Cocolios, Thomas Elias (KU Leuven (BE))
Targeted Alpha Therapy (TAT) is a very promising approach for cancer treatment in nuclear medicine [1]. It suffers however greatly from the difficult access to suitable α-decaying isotopes so that only one radiopharmaceutical for α therapy has currently received FDA approval, namely 223RaCl2 under the brand Xofigo®. [...]
MED-024.- Geneva : CERN, 2019 - 3. Fulltext: DOC;

Detaljnije - Slični zapisi
2019-03-15
16:24
Imaging of iron metabolism
Iron is an essential and critical trace metal in the human body as it is involved in many vital processes like oxygen transport and redox reactions. However, excess iron is toxic and can cause oxidative stress (Dev, 2017). [...]
MED-023.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Detaljnije - Slični zapisi